Pterostilbene
Best-in-class: Pterostilbene
A blueberry-derived cousin of resveratrol that is far more bioavailable and longer-lasting — a sirtuin-activating longevity and metabolic compound (paired with NR in ResveraCel/Basis).
Pterostilbene quick facts
| Suggested dose | 50–150 mg daily. |
| How often | Daily |
| Who it's for | Longevity, metabolic and cognitive-aging experimenters. |
Inherits both the mechanism and the uncertainty, with better delivery. One finding worth knowing before adding it to a longevity stack: at higher doses it raised LDL cholesterol in a human trial, which is an awkward result for a compound taken for cardiovascular ageing. Frequently combined with NAD+ precursors on the sirtuin rationale, which rests on the contested part of the story.
How Pterostilbene actually works
A dimethylated analog of resveratrol. The two methoxy groups make it considerably more lipophilic and resistant to glucuronidation, so oral bioavailability and half-life are both substantially higher — this is the same mechanism with a fixed pharmacokinetic profile.
Where to get Pterostilbene
Find Pterostilbene on iHerb →The evidence for Pterostilbene
Graded by what exists behind each claim.
✅ Clinically validated
- Small RCTs show effects on cholesterol and blood pressure; strong antioxidant and metabolic activity in studies.
- Better absorbed and more stable than resveratrol.
📊 Correlative data
- Polyphenol intake is broadly associated with cardiometabolic benefit.
🧪 Theoretical / extrapolated benefits
- Sirtuin/longevity promise is strong in animals; human healthspan outcomes remain unproven.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pterostilbene actually does
Pterostilbene is trans-3,5-dimethoxy-4'-hydroxystilbene. Resveratrol is trans-3,5,4'-trihydroxystilbene. Two methoxy groups where resveratrol has two hydroxyls: that is the entire chemical difference, and it is also the entire pharmacological argument.
Why two methyl groups change everything. Phenolic hydroxyls are the handles that phase II metabolism grabs. UDP-glucuronosyltransferases and sulfotransferases in the enterocyte and the liver conjugate free hydroxyls, and the conjugate is water-soluble, rapidly excreted and mostly inactive at the target. Resveratrol has three such handles and is conjugated so completely on first pass that unchanged parent is barely detectable in plasma — the general case for polyphenols Manach 2005. Methylating positions 3 and 5 removes two of the three. Pterostilbene arrives with one free hydroxyl to defend, and its circulating metabolite profile is correspondingly dominated by conjugation at that single remaining position Wang 2022. The methyl groups also raise lipophilicity, which improves passive membrane crossing and is the reason this molecule is studied for central nervous system effects that resveratrol cannot reach.
The sirtuin claim, stated honestly. Pterostilbene is sold as a SIRT1 activator, SIRT1 being the NAD+-dependent deacetylase that removes acetyl groups from PGC-1alpha, p53 and the FOXO family. The problem the marketing skips is that the original stilbene sirtuin-activation assays used a fluorophore-tagged peptide substrate, and the activation largely disappeared when the tag was removed — the substrate-dependence controversy that has followed resveratrol for two decades. Whatever pterostilbene does, calling it direct SIRT1 activation is a claim the assay history does not support, and no human trial has ever measured the acetylation state of a single SIRT1 substrate.
The mechanism that actually explains the human results is different, and it is the one nobody names. In the human trial, LDL cholesterol went up by 17.1 mg/dL while blood pressure went down Riche 2014. That combination — rising LDL alongside metabolic improvement — is the signature of PPAR-alpha agonism, which is what fibrates do: activating PPAR-alpha induces lipoprotein lipase and accelerates the conversion of triglyceride-rich VLDL into LDL particles, so measured LDL cholesterol can rise even as triglycerides fall. It is a documented and well-recognized effect of fenofibrate in hypertriglyceridemic patients. This is labeled extrapolation — nobody has demonstrated PPAR-alpha engagement by pterostilbene in a human Tian 2024 — but it is the only common mechanism that predicts the exact pattern the trial found, and it is testable in an afternoon.
Cell, rodent, human — and where it stops
In cells. Stilbenes on hepatocyte, endothelial and adipocyte lines at 10–100 micromolar, reading AMPK phosphorylation, Nrf2 targets and inflammatory transcription Tian 2024. This is the concentration range where nearly every polyphenol looks impressive.
In rodents. Oral dosing in rats and mice at 10–100 mg/kg for weeks, in metabolic, neurological and oncology models Tian 2024, with metabolite identification confirming that the compound is absorbed and then conjugated at its one free hydroxyl Wang 2022. A 40 mg/kg mouse dose is roughly 3.2 mg/kg human-equivalent by body-surface scaling — about 225 mg for a 70 kg adult, which is above almost every label.
In people, once, and it is the most important trial in this cohort. Eighty adults took pterostilbene at 50–125 mg twice daily for six to eight weeks in a randomized, double-blind, placebo-controlled trial. Systolic blood pressure fell 7.8 mmHg (P < 0.01) and diastolic fell 7.3 mmHg (P < 0.001) — a genuinely large effect for a supplement. And LDL cholesterol rose by 17.1 mg/dL, P = 0.001 Riche 2014. The safety analysis of the same trial was published separately Riche 2013, and the LDL finding was considered important enough to be restated as a standalone communication in a clinical nutrition journal Brenner 2019.
The specific obstacle is the one this page exists to state: the only substantial human trial found harm on the marker that matters most. Seventeen milligrams per deciliter is not a rounding error. It is roughly the magnitude, in reverse, of what a low-dose statin achieves. For a compound bought as a longevity intervention, moving the single most causally established risk factor for atherosclerotic cardiovascular disease in the wrong direction is not a footnote in the safety section — it is the headline result Riche 2014Brenner 2019.
The second obstacle is that everything else is extrapolation. One trial, 80 people, eight weeks maximum, no longevity endpoint, no cognitive endpoint, no cancer endpoint. The animal work is considerable Tian 2024; the human work is one study whose headline finding was unfavorable.
Pterostilbene — which form, and does it matter
Pterostilbene is a single defined molecule, which removes most of this section's usual arguments and leaves two real ones. There is no extract, no standardization percentage and no plant part to argue about: the material is synthetic or semi-synthetic trans-pterostilbene of stated purity. Ask for the purity and the isomer.
The isomer matters and is almost never printed. Stilbenes exist as trans and cis isomers, and the trans form is the active and the studied one. Trans-to-cis isomerization is driven by ultraviolet light, which is why these compounds belong in opaque bottles and why a clear jar on a shop windowsill is a defect rather than a display choice.
The dose in the human trial is the dose to reason from, and it is higher than most labels. Fifty to 125 mg twice daily Riche 2014 — that is 100 to 250 mg a day. The site's own card gives 50–150 mg daily, which straddles the bottom of the tested range. That difference is not academic: the LDL rise was observed across the tested doses, so a reader taking 50 mg once daily is below the trial and should not assume they have escaped the finding without measuring.
The nicotinamide riboside pairing is a commercial decision, not a tested one. Pterostilbene is most often sold combined with NR, on the reasoning that a sirtuin activator and an NAD+ precursor should be synergistic. No trial has tested the combination against pterostilbene alone for any endpoint, and none has reported LDL in that setting. The pairing inherits the LDL question and has not answered it Brenner 2019.
What would have to be true, and how you would know it was not
1. LDL cholesterol UP by 10–20 mg/dL at eight weeks on 100–250 mg/day. This is the prediction that cuts against the product, and it is the most strongly evidenced prediction on this page. The trial number is 17.1 mg/dL at P = 0.001 Riche 2014. Eight weeks is the right window because the circulating LDL pool re-equilibrates within about three weeks of a change in production or clearance, so by two months the new steady state is fully expressed. Draw a lipid panel before you start. Not after — a post-hoc LDL with nothing to compare it to answers nothing.
2. ApoB is the arbiter, and nobody has measured it. Two very different things can raise LDL cholesterol: more LDL particles, or the same number of particles each carrying more cholesterol. The first is atherogenic and the second is largely not. Predict, from the fibrate-like mechanism above, that ApoB rises proportionally less than LDL-C — and note clearly that this is reasoning rather than data, because no pterostilbene trial has ever reported ApoB. If ApoB rises as much as LDL-C, the particle count really went up and the compound is a net cardiovascular negative.
3. Triglycerides down 10–20% at the same visit. This is the test of the PPAR-alpha explanation. Fibrate-like activity lowers triglycerides while raising LDL-C. If LDL-C rises and triglycerides rise too, the mechanism is not PPAR-alpha and something less benign is happening to lipoprotein metabolism Riche 2014.
4. Blood pressure down 5–8 mmHg systolic by six to eight weeks. This is the trial's favorable finding and it is a large one Riche 2014. Measure it properly: home cuff, seated, same time each morning, seven consecutive days averaged, before and after. This is the one endpoint on this page where the evidence points toward the product rather than away from it.
What will fool you: feeling good. There is no subjective read-out for either the blood-pressure benefit or the LDL cost, which means the only honest way to run this compound is with two numbers, both measured, and a decision rule agreed in advance about what LDL rise would make you stop.
What nobody has tested yet
Nobody has measured ApoB or Lp(a) in a pterostilbene trial. This is the missing experiment and it is almost free: the trial that found the LDL rise already drew the blood Riche 2014. Repeat it with ApoB, non-HDL cholesterol and Lp(a) as pre-specified endpoints and the entire risk question resolves in eight weeks. Until somebody does, every reader of this page is choosing between a measured blood-pressure benefit and an unquantified particle risk.
No trial has gone above 250 mg/day, and no trial has gone beyond eight weeks. Riche 2014Riche 2013 The dose–response of the LDL effect is therefore unknown in both directions: nobody knows whether 50 mg/day is below the threshold, and nobody knows whether the rise plateaus, worsens or reverses over six months. For a compound taken indefinitely, that is a remarkable gap.
The PPAR-alpha hypothesis has never been tested. A PPAR response-element reporter assay with pterostilbene and its major conjugated metabolites Wang 2022 would take a week and would either explain the human lipid result or eliminate the only mechanism that currently does.
And nobody has measured a sirtuin substrate in a human. Acetylated p53 or acetylated PGC-1alpha in peripheral blood mononuclear cells, before and after four weeks, is a single extra tube and it is the direct read-out of the mechanism the whole longevity claim rests on. Its absence after two decades of stilbene research is the most conspicuous hole in this literature.
Pterostilbene — its own safety story, not its category's
The LDL rise is this compound's safety story, and it belongs here rather than in a footnote. A reproducible 17.1 mg/dL increase in LDL cholesterol Riche 2014, restated as a standalone communication in the clinical nutrition literature Brenner 2019, is a pharmacological effect in the wrong direction on the risk factor with the strongest causal evidence in cardiovascular medicine. If you have a family history of early coronary disease, a raised Lp(a), a coronary calcium score above zero, or you are taking a statin precisely to hold LDL down, this compound is working against the thing you are paying that statin to do.
The rule that follows is concrete. Lipid panel before starting, repeat at eight weeks, and decide in advance what would make you stop — a 15 mg/dL rise is a reasonable line. Nobody who takes this without measuring will ever know which side of that line they landed on, because there is no symptom.
Bleeding risk, and the bioavailability makes it worse rather than better. Stilbenes inhibit platelet aggregation, and pterostilbene's improved oral exposure Wang 2022 means the pharmacodynamic effect arrives more reliably than resveratrol's does. Additive with warfarin, apixaban, rivaroxaban, clopidogrel and aspirin at any dose. This is pharmacodynamic, not metabolic — it will not show up as a changed drug level, it shows up as bruising, nosebleeds or a raised INR. Two weeks off before surgery.
Blood pressure, additive and clinically large. A 7.8 mmHg systolic and 7.3 mmHg diastolic fall Riche 2014 is bigger than many single antihypertensive agents produce. Stacked on an existing regimen that is a real risk of symptomatic hypotension, particularly in older readers on a diuretic or an alpha-blocker. Measure in the first two weeks.
And the honest boundary. The human safety analysis covers one trial of 80 people for six to eight weeks Riche 2013. There is no long-term human safety data at all, and the compound is sold for indefinite daily use. Gastrointestinal upset at higher doses is the common tolerability complaint and is the least of the issues on this page.
Sources read for this page
- Riche DM, et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial.. Evidence-Based Complementary and Alternative Medicine 2014 · PMID 25057276
- Riche DM, et al. Analysis of safety from a human clinical trial with pterostilbene.. Journal of Toxicology 2013 · PMID 23431291
- Brenner C, et al. Pterostilbene raises low density lipoprotein cholesterol in people.. Clinical Nutrition 2019 · PMID 30482564
- Wang H, et al. Comprehensive Analysis of Pterostilbene Metabolites In Vivo and In Vitro Using a UHPLC-Q-Exactive Plus Mass Spectrometer with Multiple Data-Mining Methods. ACS Omega 2022 · PMID 36340088
- Tian R, et al. Effects of Pterostilbene on Cardiovascular Health and Disease. Current Issues in Molecular Biology 2024 · PMID 39329921
- Manach C, et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies.. American Journal of Clinical Nutrition 2005 · PMID 15640486
How you would know if it worked
The sirtuin and longevity framing has no read-out in a human being on any timeline you will live through. The lipid effect does, and it is a reason to draw blood rather than a reason to buy: the small human trials here are described as showing effects on cholesterol, and 'effects' is a direction-free word doing a lot of work. So a lipid panel with ApoB before and after is a check, not a victory lap — and if LDL or ApoB went up on a supplement bought for longevity, that is the most important thing the bottle will ever tell you.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) Retest: Every 3–6 months on androgens; annually otherwise.
- ApoB (Apolipoprotein B) Retest: Every 3–6 months on androgens or after any intervention; annually otherwise.
The cheapest panel carrying Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and at least one other of these is Metabolic Health & Prediabetes, at $90 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Pterostilbene — safety & side effects
- Well tolerated; GI upset at higher doses.
- Raises LDL cholesterol — this was a reproducible finding in the human trial and is the distinctive thing to know about it versus resveratrol.
- Antiplatelet activity and CYP inhibition, as with resveratrol. Additive bleeding risk with anticoagulants and antiplatelets — warfarin, apixaban, rivaroxaban, clopidogrel, and aspirin at any dose. The interaction is pharmacodynamic rather than metabolic, so it does not show up as a changed drug level; it shows up as bruising, nosebleeds or a raised INR.
- Better bioavailability than resveratrol, which means the effects and the interactions both arrive more reliably.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Pterostilbene in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pterostilbene
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammation these are aimed at |
| ApoB (Apolipoprotein B) | Cardiovascular risk, measured properly |
| HbA1c (Hemoglobin A1c) | Glycation over three months |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pterostilbene — frequently asked questions
What is Pterostilbene?
A blueberry-derived cousin of resveratrol that is far more bioavailable and longer-lasting — a sirtuin-activating longevity and metabolic compound (paired with NR in ResveraCel/Basis).
What is the suggested dose of Pterostilbene?
50–150 mg daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Pterostilbene dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Pterostilbene?
Coach Cam sources Pterostilbene from vetted, top-rated brands on iHerb — use the buy link on this page.
Pterostilbene inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Pterostilbene is used for
Pterostilbene appears under 2 goals in the goal router.
Related Longevity & Antioxidants supplements
Where this goes next
Pterostilbene is the nad+ arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.